180 Life Sciences Corp

NASDAQ:ATNF   3:59:54 PM EDT
2.75
-0.29 (-9.54%)
Products, Regulatory

180 Life Sciences Provides Follow-Up Information On Oxford University And The Company’S Successful Dupuytren’S Phase 2B Clinical Trial Results

Published: 12/06/2021 14:51 GMT
180 Life Sciences Corp (ATNF) - 180 Life Sciences Provides Follow-up Information on Oxford University and the Company’s Successful Dupuytren’s Phase 2b Clinical Trial Results.
180 Life Sciences Corp - Both Primary and Secondary Endpoints From Phase 2b Clinical Trial for Dupuytren's Disease Were Statistically Significant.
180 Life Sciences Corp - Initial Meetings With FDA and Mhra Currently Planned for H1 2022.